Q1 FY27 results analysis · August 05, 2026

Sudeep Pharma Ltd (SUDEEPPHRM) Q1 FY27 Results Analysis: PAT Surges 31.6%, EBITDA Margin Misses Target

+31.6%PAT year on year, Rs. 40.59 Cr
Cofacto ResearchPublished August 05, 20262 min readPositive read
Quick summary

Sudeep Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 158.27 Cr (+26.70% YoY) and PAT growth of +31.63% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 04, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 158.27 Cr (+26.70% YoY)
PAT (Q1)Rs. 40.59 Cr (+31.63% YoY)
EBITDA margin34.69% (-43 bps YoY)
EPS (Q1)Rs. 3.59 (+26.41% YoY)
Market capRs. 10,860.48 Cr
CMPRs. 958.95

Quarter Snapshot

Strong Q1 with 26.7% revenue growth and 31.6% PAT growth. The Pharma, Food & Nutrition segment beat management's >10% guidance by a wide margin. However, gross margin compression and elevated employee costs kept EBITDA margin below the 37-38% target. The Nandesari Unit IV capex and US tailwinds provide near-term catalysts, but margin recovery is still a work in progress.

Key Investment Insights

Key Positives

  • Pharma, Food & Nutrition segment revenue grew 30.64% YoY to Rs.108.41 Cr, exceeding management's >10% full-year guidance.
  • Consolidated revenue grew 26.70% YoY to Rs.158.27 Cr.
  • PAT attributable to owners grew 31.63% YoY to Rs.40.55 Cr.
  • Standalone revenue grew 31.82% YoY, faster than consolidated.
  • EBITDA margin improved sequentially from 34.33% to 34.69%.
  • Subsidiary contribution to PAT increased to Rs.6.72 Cr from Rs.5.60 Cr a year ago.

Risk Factors

  • Gross margin compressed 187 bps YoY to 64.25% due to pass-through of raw material price reductions in contracts.
  • Specialty Ingredients EBITDA margin fell to 30.53% from 40.68% a year ago.
  • Employee costs spiked 36.31% QoQ, pressuring near-term margins.
  • EBITDA margin of 34.69% remains 231-331 bps below the stated target of 37-38%.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.